Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 1, 2008, Pages 7-13

  Shimizu, Tomomi ^a   Hino, Akane ^a   Tsutsumi, Atsuko ^a,b   Yong, Kun Park ^c   Watanabe, Wataru ^a   Kurokawa, Masahiko ^a  

^a KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b AMAZONFOOD Ltd   (Japan)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AF 08; ALCOHOL; OSELTAMIVIR; PROPOLIS; RIBAVIRIN; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIRUS CULTURE; WEIGHT REDUCTION; ANIMAL; BRAZIL; DBA MOUSE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; INFLUENZA VIRUS A H1N1; LUNG; ORAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; VIROLOGY; VIRUS LOAD;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BRAZIL; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; MICE, INBRED DBA; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PLAQUE ASSAY; PROPOLIS; VIRAL LOAD; WEIGHT LOSS;

EID: 47049124066     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900102     Document Type: Article

References (34)

1. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 55:1845-1850.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.
3. Hayden FG. Amantadine and rimantadine-clinical aspects. In Antiviral Drug Resistance. Edited by DD Richman. Chichester, United Kingdom: John Wiley & Sons Ltd. Press; 1996. pp. 59-77.
4. Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol 2001; 1:482-490.
5. Pitt SR. Evidence-based emergency medicine/systematic review abstract. Use of the neuraminidase inhibitor class of antiviral drugs for treatment of healthy adults with an acute influenza-like illness. Ann Emerg Med 2002; 39:552-554.
6. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-1424.
7. McKimm BJ, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-2272.
8. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-750.
9. Bankova V, Christov R, Kujumgiev A, Marcucci MC, Popov S. Chemical composition and antibacterial activity of Brazilian propolis. Z Naturforsch [C] 1995; 50:167-172.
10. Banskota AH, Tezuka Y, Kadota S. Recent progress in pharmacological research of propolis. Phytother Res 2001; 15:561-571.
11. Burdock GA. Review of the biological properties and toxicity of propolis. Food Chem Toxicol 1998; 36:341-363.
12. Khalil ML. Biological activity of bee propolis in health and disease. Asian Pac J Cancer Prev 2006; 7:22-31.
13. Inokuchi Y, Shimazawa M, Nakajima Y, Suemori S, Mishima S, Hara H. Brazilian green propolis protects against retinal damage in vitro and in vivo. Evid Based Complement Alternat Med 2006; 3:71-77.
14. Kujumgiev A, Tsvetkova I, Serkedjieva Y, Bankova V, Christov R, Popov S. Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. J Ethnopharmacol 1999; 64:235-240.
15. Ito J, Chang FR, Wang HK, et al. Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis. J Nat Prod 2001; 64:1278-1281
16. Park YK, Alencar SM, Aguiar CL. Botanical origin and chemical composition of Brazilian propolis. J Agric Food Chem 2002; 50:2505-2506.
17. Park YK, Fukuda I, Ashida H, Nishiumi S. Suppression of dioxin mediated aryl hydrocarbon receptor transformation by ethanolic extracts of propolis. Biosci Biotechnol Biochem 2004; 68:935-938.
18. Serkedjieva J, Manolova N, Bankova V. Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids). J Nat Prod 1992; 55:294-302.
19. Kurokawa M, Ochiai H, Nakajima K, Niwayama S. Inhibitory effect of protein kinase C inhibitor on the replication of influenza type A virus. J Gen Virol 1990; 71:2149-2155
20. Kurokawa M, Imakita M, Kumeda CA, Shiraki K. Cascade of fever production in mice infected with influenza virus. J Gen Virol 1996; 50:152-158.
21. Shin K, Wakabayashi H, Yamauchi K, et al. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J Med Microbiol 2005; 54:717-723.
22. Tsurita M, Kurokawa M, Imakita M, Fukuda Y, Watanabe Y, Shiraki K. Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 2001; 298:362-368.
23. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50:219-244.
24. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42:640-646.
25. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/ Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192:665-672.
26. Kurokawa M, Kumeda CA, Yamamura J, Kamiyama J, Shiraki K. Antipyretic activity of cinnamyl and related Compounds in Kakkon-to, a traditional medicine, in influenza virus-infected mice. Eur J Pharmacol 1998; 348:45-51.
27. Kurokawa M, Tsurita M, Brown J, Fukuda Y, Shiraki K. Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice. Antivir Res 2002; 56:183-188.
28. Mori K, Kido T, Daikuhara H, et al. Effect of Hochuekki-to (TJ-41), a Japanese herbal medicine, on the survival of mice infected with influenza virus. Antivir Res 1999; 44:103-111.
29. Elena A, Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45:2723-2732.
30. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-981.
31. Chand P, Bantia S, Kotian PL, El-Kattan Y, Lin TH, Babu YS. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem 2005; 13:4071-4077.
32. Teixeira EW, Negri G, Meira RM, Message D, Salatino A. Plant origin of green propolis: bee behavior, plant anatomy and chemistry. Evid Based Complement Alternat Med 2005; 2:85-92.
33. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12:143-156.
34. Kostense S, Sun WH, Cottey R, et al. Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice. Antivir Res 1998; 38:117-130.